Tysabri gets positive review for Crohn’s disease in US

Two FDA advisory panels recommended approving Tysabri for patients with moderate-to-severe Crohn’s disease who have failed on other drugs. Marketed by Biogen Idec and Elan, Tysabri is already approved for MS. An approval in this Crohn’s population may not boost the drug’s profits very much, but the advisory panels’ decision suggests concerns about the drug’s safety were tempered by its benefits. Tysabri has been linked to a rare viral infection of the brain (PML) and was temporarily withdrawn.

- see this release from Elan

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

Suggested Articles

The new Community trial will first test Amgen's Otezla, Takeda's Takhzyro and UCB's zilucoplan in hospitalized patients.

Indivior faces a new lawsuit from RB, its former parent company, over a scheme to market opioid addiction therapy Suboxone Film.

A new FDA effort brings cancer drug labels to life in videotaped panels with experts, debuting its first episode on Seagen's MBC med Tukysa.